Abstract
AXT Inc will report its first-quarter 2026 financial results on April 30, 2026 Post Market; this preview compiles the latest quarterly actuals, current-quarter forecasts, and recent analyst commentary to frame expectations around revenue, profitability, and earnings trajectory.Market Forecast
The market is looking for a sequential upturn in the March quarter, with AXT Inc’s revenue projected at 26.22 million US dollars, implying an estimated year-over-year increase of 38.12%; consensus points to an adjusted EPS loss of about -0.05 with a 66.47% year-over-year improvement, and EBIT of approximately -2.68 million US dollars improving 60.12% year-over-year. Guidance specifics for gross margin and net margin are not available in the current forecast set; the company’s prior commentary indicated a sequential revenue lift, consistent with these expectations.The company’s core business remained concentrated in substrates last quarter, which accounted for roughly two-thirds of revenue and should continue to anchor performance as order activity normalizes; raw materials and other revenues comprise the remaining one-third and provide an additional cushion to top-line variability. The most promising contributor within the portfolio remains the substrates category, which represented about 15.36 million US dollars last quarter; current-quarter revenue is expected to improve from that base alongside the anticipated overall growth.
Last Quarter Review
In the December quarter (Q4 2025), AXT Inc delivered revenue of 23.04 million US dollars, a gross profit margin of 20.95%, a GAAP net loss attributable to shareholders of -3.55 million US dollars with a net margin of -15.40%, and adjusted EPS of -0.05, reflecting a 8.22% year-over-year revenue decline and a 50.00% year-over-year improvement in EPS. A key highlight was the earnings quality relative to expectations: while revenue undershot the prior projection, EPS was better than anticipated, and EBIT also surpassed estimates modestly.Within the business mix, substrates were the central revenue engine, representing approximately 66.68% of quarterly sales, or about 15.36 million US dollars, while raw materials and other categories contributed about 7.69 million US dollars; the mix indicates a concentrated topline, with execution in substrates exerting the greatest influence on quarterly performance.
Current Quarter Outlook
Main business: Substrates
Substrates remain the primary revenue driver for the March quarter. With last quarter’s mix indicating about two-thirds of revenue in this area, the forecasted company-wide revenue growth to 26.22 million US dollars implies an incremental lift for substrates in absolute dollars if mix proportions hold near recent levels. The fourth quarter gross margin of 20.95% provides a baseline for assessing profitability; any sequential throughput gains or richer product mix would support margin carry-through on higher volumes, although mix and utilization shifts can introduce variability around gross margin in short intervals. Operational execution in backlog conversion, delivery timing, and production efficiency will be central to translating a sequential revenue uptick into improved contribution margin and narrowing losses.From a profit-bridge perspective, the March quarter’s EPS expectation of around -0.05 and EBIT at approximately -2.68 million US dollars reflect material year-over-year improvement embedded in consensus. For substrates specifically, the path to earnings progress in the near term connects to higher absorption of fixed costs as volume steps up from the December quarter trough, and to product mix, where a larger share of higher-value substrate shipments would support gross profit dollars. As the company executes on sequential growth, the focus for investors will be whether the gross margin can maintain or expand from the Q4 level despite ongoing cost inputs, and whether operating expenses remain disciplined so that incremental gross profit drops meaningfully to operating results.
Most promising business: Substrates-led growth vector
Within the company’s portfolio, substrates represented about 15.36 million US dollars of last quarter’s revenue based on mix, and are positioned to contribute most of the near-term upside if the expected top-line recovery materializes. While explicit segment-level year-over-year growth metrics are not available, the consolidated revenue forecast implies an acceleration relative to last year’s March quarter, and the improvement in the EPS and EBIT forecasts points to operating leverage as volumes rebuild. The key determinant for this “most promising” vector is the pace of order fulfillment and shipment timing within the March quarter versus early in the June quarter, since even modest timing shifts can swing reported margins and EPS across quarters.Pricing discipline and product yield remain important operational levers. If the company preserves pricing while improving yields on more advanced substrate specifications, contribution margins can expand on top of higher volumes. Conversely, if product mix skews toward lower-margin configurations or if yields lag expectations, the benefit to operating income may be more muted even with topline growth. Investors will parse management’s color on shipments and mix at the release to assess whether the upward inflection in revenues is translating proportionately into gross profit dollars and a narrower loss trajectory.
Key stock-price swing factor: Equity offering and share-count implications
A material development in the current period is the underwritten public stock offering priced at 64.25 US dollars per share, with gross proceeds targeted at approximately 550 million US dollars and a 30-day overallotment option. The company indicated that proceeds will primarily support its Beijing Tongmei Xtal Technology unit and general corporate purposes. This capital raise has two concurrent implications for the coming quarters: near-term dilution to per-share metrics and longer-term capacity and capability funding that can underpin revenue scalability and cost efficiency.In the short run, incremental shares outstanding can pressure per-share results, especially while the company is still operating at a loss. As the current-quarter adjusted EPS consensus is approximately -0.05, any substantial increase in average diluted share count may mechanically hold back per-share improvement even if operating income trends better than expected. In the medium term, if proceeds accelerate production readiness, improve manufacturing efficiency, or de-bottleneck supply constraints, the added capacity can support sequential revenue growth beyond Q1 and improve gross margin via more favorable absorption. The balance investors will watch is pacing: whether the investment payback in revenue and margin expansion offsets the dilution footprint within a reasonable timeframe.
Analyst Opinions
Bullish views dominate recent published commentary in the current period, with favorable ratings outnumbering cautious ones. Two well-followed research houses reiterated positive stances: Craig-Hallum maintained a Buy rating and a notably higher price objective in its latest communication during this window, and Northland Securities also reiterated a Buy rating with an updated target. Another firm, B. Riley, raised its target to 72 US dollars while maintaining a Neutral stance; meanwhile, broader survey work shows an average rating that tilts positive. On balance, the ratio of bullish to bearish opinions in the recent period skews toward bullish, with neutral commentary providing additional context but not altering the directional majority.The core of the bullish case centers on the expected sequential revenue improvement in the March quarter and a clear year-over-year improvement profile embedded in consensus: revenue estimated at 26.22 million US dollars (+38.12% year over year), EBIT improving to about -2.68 million US dollars (+60.12% year-over-year improvement), and adjusted EPS guided by the street at roughly -0.05 (+66.47% year-over-year improvement). Supportive analysts argue that the company’s topline trajectory is inflecting off the December quarter and that operating leverage should begin to appear as volume rebuilds, with the potential for margins to stabilize near or above the Q4 20.95% gross margin baseline as fixed-cost absorption improves. They also acknowledge the share issuance introduces dilution, but frame the proceeds as strategically accretive to medium-term revenue capacity and operational flexibility, particularly as the company works to align supply with order visibility and to streamline production.
In parsing institutional commentary, favorable ratings emphasize several tangible signposts to track into the April 30, 2026 release. The first is execution on the sequential revenue guide and whether bookings and shipments align with the forecasted 26.22 million US dollars outcome; meeting or beating that top-line marker is viewed as a near-term validator of the recovery narrative. The second is the degree of improvement in operating metrics: even small gains in gross margin from the Q4 level can translate to disproportionate gains in EBIT given an expected revenue step-up, suggesting that downside risk to the -2.68 million US dollars EBIT estimate may be balanced by upside if mix and yields cooperate. The third is management’s color on capital deployment following the offering—clarity around timelines for capacity-related spending and expected throughput improvements will help investors handicap the trajectory of revenue and margin expansion into the June quarter and beyond.
In summary, the prevailing institutional view is constructive ahead of the April 30, 2026 report, grounded in a forecasted return to top-line growth against last year’s March quarter and a marked year-over-year improvement in losses, with particular attention on substrates performance and the translation of higher volumes into margin gains. While share dilution is a recognized headwind for per-share figures, supportive analysts see a credible path for the company to leverage fresh capital into operational enhancements that can sustain revenue growth and gradually compress operating losses over the next set of quarters if execution remains consistent.
Comments